| London Stock Exchange: EHP
EpiStem Holdings Plc provides pre-clinical solutions. It is a biotechnology company that is commercializing adult stem cells in the areas of oncology and gastrointestinal diseases, as well as cosmeceutical applications. The company develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. It operates in three divisions: Contract Research Services, Biomarkers and Novel Therapies. The Contract Research Services division offers specialized preclinical efficacy testing and clinical sample analysis to the pharmaceutical, biotechnology and personal care industries which provides preclinical models in four key therapeutic areas, such as oncology, supportive care, inflammatory bowel disease and dermatology. The Biomarkers division is designed to identify changes in gene expression that result from treatment with an oncology drug. The Novel Therapeutics division discovers the key regulators of adult epithelial stem cells and developing protein therapeutics that control cell production in the areas of oncology, oncology supportive care and epithelial disease. EpiStem Holdings was founded by Chris Potten and Catherine Booth in 2000 and is headquartered in Manchester, the United Kingdom.